# Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

> **NCT05502731** · PHASE4 · UNKNOWN · sponsor: **Leiden University Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT05502731
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2025-03
- **Final completion:** 2025-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05502731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05502731, "Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05502731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*